-
Sunitinib, sold
under the
brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted
receptor tyrosine kinase (RTK) inhibitor...
-
effectiveness of
everolimus in
carcinoid tumors have not been established.
sunitinib (Sutent) is
labeled for
treatment of progressive, well-differentiated...
-
randomized study of
zanzalintinib in
combination with
nivolumab versus sunitinib in
patients with
advanced or
metastatic non-clear cell RCC (nccRCC). Sharma...
- (NSCLC).
Sunitinib is an oral drug that
inhibits the
phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF.
Sunitinib is used in...
-
cytokine therapy (IL-2, interferon),
kinase inhibitors (temsirolimus,
sunitinib, sorafenib, pazopanib) and anti-angiogenic
therapies (bevacizumab). "Clear...
-
approved within the past ten years.
These treatments are:
Nivolumab Axitinib Sunitinib Cabozantinib Everolimus Lenvatinib Pazopanib Bevacizumab Sorafenib Tivozanib...
- shut down in 2003,
after developing the
pioneering kinase inhibitor drug
sunitinib (Sutent).
Sugen was
founded in 1991 in
Redwood City, California, by veteran...
- multiple-tyrosine-kinase
inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31 The
effectiveness of
imatinib and
sunitinib depends on the genotype...
-
treatment for
patients with
advanced kidney cancer after failure of
either sunitinib or sorafenib" (Press release). Novartis. 30
March 2009.
Archived from...
-
inhibitor that is
effective both as a
senolytic and as
therapy for CML.
Sunitinib, an
inhibitor of the
receptors for FGF, PDGF and VEGF is also
based on...
